IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-023-44243-6.html
   My bibliography  Save this article

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity

Author

Listed:
  • Sheng Wang

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Sebastian O. Klein

    (University of Freiburg)

  • Sylvia Urban

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Maximilian Staudt

    (Albert-Ludwigs-Universität Freiburg)

  • Nicolas P. F. Barthes

    (Albert-Ludwigs-Universität Freiburg)

  • Dominica Willmann

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Johannes Bacher

    (Albert-Ludwigs-Universität Freiburg)

  • Manuela Sum

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Helena Bauer

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Ling Peng

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Georg A. Rennar

    (Albert-Ludwigs-Universität Freiburg)

  • Christian Gratzke

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Katrin M. Schüle

    (Faculty of Medicine, University of Freiburg)

  • Lin Zhang

    (Albert-Ludwigs-Universität Freiburg)

  • Oliver Einsle

    (Albert-Ludwigs-Universität Freiburg)

  • Holger Greschik

    (Klinikum der Albert-Ludwigs-Universität Freiburg)

  • Calum MacLeod

    (Drug Discovery, Pharmaron UK Ltd)

  • Christopher G. Thomson

    (Drug Discovery, Pharmaron UK Ltd)

  • Manfred Jung

    (University of Freiburg
    Albert-Ludwigs-Universität Freiburg
    Deutsches Konsortium für Translationale Krebsforschung, Standort Freiburg)

  • Eric Metzger

    (Klinikum der Albert-Ludwigs-Universität Freiburg
    Deutsches Konsortium für Translationale Krebsforschung, Standort Freiburg)

  • Roland Schüle

    (Klinikum der Albert-Ludwigs-Universität Freiburg
    University of Freiburg
    Deutsches Konsortium für Translationale Krebsforschung, Standort Freiburg)

Abstract

Inhibition of epigenetic regulators by small molecules is an attractive strategy for cancer treatment. Recently, we characterised the role of lysine methyltransferase 9 (KMT9) in prostate, lung, and colon cancer. Our observation that the enzymatic activity was required for tumour cell proliferation identified KMT9 as a potential therapeutic target. Here, we report the development of a potent and selective KMT9 inhibitor (compound 4, KMI169) with cellular activity through structure-based drug design. KMI169 functions as a bi-substrate inhibitor targeting the SAM and substrate binding pockets of KMT9 and exhibits high potency, selectivity, and cellular target engagement. KMT9 inhibition selectively downregulates target genes involved in cell cycle regulation and impairs proliferation of tumours cells including castration- and enzalutamide-resistant prostate cancer cells. KMI169 represents a valuable tool to probe cellular KMT9 functions and paves the way for the development of clinical candidate inhibitors as therapeutic options to treat malignancies such as therapy-resistant prostate cancer.

Suggested Citation

  • Sheng Wang & Sebastian O. Klein & Sylvia Urban & Maximilian Staudt & Nicolas P. F. Barthes & Dominica Willmann & Johannes Bacher & Manuela Sum & Helena Bauer & Ling Peng & Georg A. Rennar & Christian , 2024. "Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-023-44243-6
    DOI: 10.1038/s41467-023-44243-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-023-44243-6
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-023-44243-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Paz Polak & Rosa Karlić & Amnon Koren & Robert Thurman & Richard Sandstrom & Michael S. Lawrence & Alex Reynolds & Eric Rynes & Kristian Vlahoviček & John A. Stamatoyannopoulos & Shamil R. Sunyaev, 2015. "Cell-of-origin chromatin organization shapes the mutational landscape of cancer," Nature, Nature, vol. 518(7539), pages 360-364, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Alexander Martinez-Fundichely & Austin Dixon & Ekta Khurana, 2022. "Modeling tissue-specific breakpoint proximity of structural variations from whole-genomes to identify cancer drivers," Nature Communications, Nature, vol. 13(1), pages 1-15, December.
    2. Luan Nguyen & Arne Hoeck & Edwin Cuppen, 2022. "Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    3. Miguel M. Álvarez & Josep Biayna & Fran Supek, 2022. "TP53-dependent toxicity of CRISPR/Cas9 cuts is differential across genomic loci and can confound genetic screening," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
    4. Michael Habig & Cecile Lorrain & Alice Feurtey & Jovan Komluski & Eva H. Stukenbrock, 2021. "Epigenetic modifications affect the rate of spontaneous mutations in a pathogenic fungus," Nature Communications, Nature, vol. 12(1), pages 1-13, December.
    5. Koon-Kiu Yan & Shaoke Lou & Mark Gerstein, 2017. "MrTADFinder: A network modularity based approach to identify topologically associating domains in multiple resolutions," PLOS Computational Biology, Public Library of Science, vol. 13(7), pages 1-22, July.
    6. Kseniia Cheloshkina & Maria Poptsova, 2021. "Comprehensive analysis of cancer breakpoints reveals signatures of genetic and epigenetic contribution to cancer genome rearrangements," PLOS Computational Biology, Public Library of Science, vol. 17(3), pages 1-23, March.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-023-44243-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.